Woodline Partners LP Grows Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

Woodline Partners LP grew its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 22.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 498,732 shares of the company's stock after acquiring an additional 91,829 shares during the quarter. Woodline Partners LP owned about 1.67% of Silence Therapeutics worth $3,431,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SLN. JPMorgan Chase & Co. acquired a new position in shares of Silence Therapeutics during the 4th quarter valued at about $26,000. Barclays PLC increased its stake in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after acquiring an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics during the 4th quarter valued at about $69,000. Virtus ETF Advisers LLC increased its stake in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after acquiring an additional 6,098 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of Silence Therapeutics during the 4th quarter valued at about $113,000. Institutional investors and hedge funds own 98.73% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. The Goldman Sachs Group dropped their price objective on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research note on Friday, May 9th. BMO Capital Markets dropped their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Chardan Capital dropped their target price on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Morgan Stanley dropped their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $33.83.

Silence Therapeutics Stock Performance

SLN traded down $0.10 on Friday, reaching $5.84. 61,907 shares of the company's stock were exchanged, compared to its average volume of 300,864. The company's 50 day moving average is $3.57 and its 200-day moving average is $5.32. The company has a market cap of $174.79 million, a price-to-earnings ratio of -3.71 and a beta of 1.20. Silence Therapeutics plc has a twelve month low of $1.97 and a twelve month high of $22.47.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). The company had revenue of $0.14 million during the quarter, compared to analysts' expectations of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. Sell-side analysts forecast that Silence Therapeutics plc will post -1.77 EPS for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.